Company News

Share this article:
Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.